<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519727</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 325568-CS1</org_study_id>
    <secondary_id>EudraCT No: 2007-000235-25</secondary_id>
    <nct_id>NCT00519727</nct_id>
  </id_info>
  <brief_title>Safety Study of ISIS 325568 in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Double-Blind, Placebo-Controlled, Dose- Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 325568 Administered to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this trial is to assess the safety of ISIS 325568 when given at
      increasing single doses and to assess the safety of the same doses when given multiple times.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety of a single subcutaneous injection of ISIS 325568 administered at four
      increasing dose levels (50, 100, 200, 400 mg/week) and to evaluate the safety and
      tolerability of multiple doses of ISIS 325568 (three intravenous doses during Study Week 1,
      followed by once weekly subcutaneous administration for 5 weeks) at each of the four dose
      levels
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>30 days for single dose, 16 weeks for multi-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups.</measure>
    <time_frame>4 days for single dose, 16 weeks for multi-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg ISIS 325568 vs Placebo, s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg ISIS 325568 vs Placebo , s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg ISIS 325568 vs Placebo , s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg ISIS 325568 vs Placebo, s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 325568</intervention_name>
    <description>4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg
Placebo: 0.9% Sodium Chloride</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>AA</arm_group_label>
    <arm_group_label>BB</arm_group_label>
    <arm_group_label>CC</arm_group_label>
    <arm_group_label>DD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 65 years

          2. Males or females. Females must be non-pregnant and non-lactating, and either
             surgically sterile (hysterectomy, oophorectomy, or tubal ligation) or post-menopausal.
             Males must be surgically sterile, abstinent or if engaged in sexual relations of
             child-bearing potential, subject or partner must be using an acceptable contraceptive
             method during the trial and for 9 weeks after the last dose of study drug.

          3. Give written informed consent to participate in study and availability for all study
             requirements

          4. Fasting plasma glucose ≤ the upper limit of the laboratory's reference range (ULN)

          5. HbA1C ≤ ULN

          6. BMI &lt; 30 kg/m2

        Exclusion Criteria:

          1. Clinically significant abnormalities in medical history or physical examination

          2. Abnormalities on laboratory examination (ALT &gt; ULN, AST &gt; ULN, bilirubin &gt; ULN,
             creatinine &gt; ULN, urine protein positive by urine dipstick, platelets &lt; lower limit of
             normal and any other clinically significant laboratory findings)

          3. History of clinically significant abnormalities in coagulation parameters

          4. Positive test result for HIV, hepatitis B virus, and/or hepatitis C virus

          5. Active infection requiring antiviral or antimicrobial therapy

          6. Subjects on chronic or acute prescription medication may be permitted after discussion
             with the Isis Medical Monitor.

          7. Malignancy (with the exception of basal or squamous cell carcinoma of the skin if
             adequately treated and no recurrence for &gt; 1 year)

          8. Any other concurrent condition which, in the opinion of the Investigator, would
             preclude participation in this study or interfere with compliance

          9. History of alcohol or drug abuse

         10. Undergoing or have undergone treatment with another investigational drug, biologic
             agent or device within 90 days prior to Screening.

         11. Blood donation within three months of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Burggraaf, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Human Drug Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2007</study_first_submitted>
  <study_first_submitted_qc>August 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2007</study_first_posted>
  <last_update_submitted>August 15, 2008</last_update_submitted>
  <last_update_submitted_qc>August 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Sanjay Bhanot, MD, VP of Research and Development</name_title>
    <organization>ISIS Pharmaceuticals Medical Monitor</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

